<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784732</url>
  </required_header>
  <id_info>
    <org_study_id>CQAV680A2202</org_study_id>
    <nct_id>NCT00784732</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber</brief_title>
  <official_title>A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness of QAV680 against placebo in treating the symptoms
      of seasonal allergic rhinitis in an Environmental Exposure Chamber.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score (TNSS) over the last 2 hours of exposure in the EEC Percentage nasal lavage eosinophil count post EEC</measure>
    <time_frame>TNSS: 6-8h during EEC exposure on Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of nasal cytokines (ECP, IL-5, IL-13, PGD2, Eotaxin)</measure>
    <time_frame>After 8h exposure in EEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute eosinophil count from nasal lavage collected</measure>
    <time_frame>During exposure in EEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal airway patency assessed by acoustic rhinometry during exposure in the EEC</measure>
    <time_frame>During exposure in EEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ocular Symptom Score measured during exposure in the EEC</measure>
    <time_frame>During exposure in EEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess pharmacokinetics of plasma QAV680 in patients with seasonal allergic rhinitis</measure>
    <time_frame>Through out study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAV680</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAV680</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive skin prick test to ragweed allergen

          -  FEV1 must be ≥80% predicted value at screening and prior to entry into EEC on Day -2.

          -  Patients must weigh at least 50 kg, and must have a body mass index (BMI) within the
             range of 18 to 35 kg/m2.

          -  Non-smokers and ex-smokers (≤10 pack years and &gt;6 months of smoking abstinence).

          -  Understand and sign the written informed consent

        Exclusion Criteria:

          -  Patients requiring a change in the use of any prescription drugs within four (4) weeks
             prior to initial dosing.

          -  Participation in any clinical investigation within four (4) weeks prior to initial
             dosing or longer if required by local regulations, and for any other limitation of
             participation based on local regulations.

          -  Significant illness within two (2) weeks prior to initial dosing.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Investigator Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14630</url>
    <description>Results for CQAV680A2202 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Seasonal Allergic Rhinitis</keyword>
  <keyword>Environmental Exposure Chamber</keyword>
  <keyword>nasal lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

